Article Text


Development of the health and economic consequences of smoking interactive model
  1. Michelle E Ormea,
  2. Susan L Hogueb,
  3. Lisa M Kennedya,
  4. Abigail C Painea,
  5. Christine Godfreyc
  1. aThe Lewin Group, Bracknell, Berkshire, UK, bGlobal Health Outcomes, Glaxo Wellcome, Research Triangle Park, North Carolina, USA, cCentre for Health Economics, University of York, York, UK
  1. Michelle Orme, The Lewin Group, Action International House, Crabtree Office Village, Eversley Way, Egham, Surrey TW208RY UKMichelle.Orme{at}


OBJECTIVE To describe the health and economic consequences of smoking model, a user friendly, web based tool, designed to estimate the health and economic outcomes associated with smoking and the benefits of smoking cessation.

RESULTS An overview of the development of the model equations and user interface is given, and data from the UK are presented as an example of the model outputs. These results show that a typical smoking cessation strategy costs approximately £1200 per life year saved and £22 000 per death averted.

CONCLUSIONS The model successfully captures the complexity required to model smoking behaviour and associated mortality, morbidity, and health care costs. Furthermore, the interface provides the results in a simple and flexible way so as to be useful to a variety of audiences and to simulate a variety of smoking cessation methods.

Statistics from

Tobacco use is associated with a number of chronic or acute diseases and enormous societal costs. Although the number of people who die or suffer illness because of its use is the best measure of the burden of tobacco, the cost to society must also be measured in terms of economic loss. Tobacco use drains economies of billions of dollars in health care costs and lost productivity each year. As an example, smoking related diseases cost the National Health Service in England between £1.4 and £1.5 billion annually,1 yet tobacco addiction is a treatable medical condition. For a relatively small initial outlay, smoking cessation interventions result in health gains, which in the long term save lives and reduce the cost of health care for smoking related diseases, releasing resources for other health care programmes.

The methodology described in this paper suggests one approach to developing an epidemiological model for smoking related diseases and the implications of smoking cessation. This methodology was driven by the needs of the end users and the need for a realistic and robust model. The health and economic consequences of smoking (HECOS) model captures the complexity required to model smoking behaviour and associated morbidity, mortality, and costs. This is shown within the paper using data from the UK as an example. The model interface presents these results in a simple, easy-to-use way, allowing different scenarios and combinations of smoking cessation aids to be considered. Users can select different strategies by changing key values. In this way, the model is flexible enough to be useful to a variety of decision makers.


The objective of this work was to develop an interactive software tool that would be widely accessible and applicable for use by health care payers, government policy makers, and other health care organisations in a variety of countries. A key purpose of the model is to show the health and economic burden that smoking related diseases place on health care systems, in addition to showing the potential disease cases averted and the reduction in the smoking related disease costs resulting from successful smoking cessation programmes. The model was commissioned by Glaxo Wellcome for the Lewin Group and offered for use by the World Health Organization (WHO) “European partnership project to reduce tobacco dependence”. The model thus currently includes the four target countries of the WHO European partnership project (UK, France, Germany, and Poland), in addition to other European Union countries, as well as Australia, China, Czech Republic, Hungary, Mexico, New Zealand, Norway, and Ukraine.

The purpose of this paper is to outline the stages in the development of the HECOS model and the methodology used to construct the model equations. Additionally, data from the UK are presented as an example of HECOS outputs.

Overview of model development

To model the burden of smoking in a given population, the relation between different smoking behaviours and the risk of smoking related disease needs to be considered. Therefore, the first stage of the development of the HECOS model was a review of available literature and consultations with appropriate specialists to obtain a comprehensive understanding of the modelling problem.

When there is no overlap between successive generations, population growth can be modelled in discrete steps. Even if a population varies continuously with time, it can be approximated by a discrete system by considering the total population at fixed time intervals. If the time between successive generations is a fixed time step, sayt, then the population at a timet+1, denoted byNt+1 , can be related to the population at time t, denoted byNt , using the equation:

Embedded Image

where f (Nt)represents, in general, a non-linear function ofNt . Discrete difference equations such as equation 1 are widely studied and have a broad range of applications, particularly in the study of population dynamics.2 3 These simple equations can exhibit complex behaviour4 and are usually impossible to solve analytically. The advantage of presenting the model equations in this way is that the variables for future time steps are stated explicitly, in terms of variables from previous time steps. Therefore, it is straightforward to evaluate such equations by using equation 1 recursively.

Markov models are commonly used in health economics to model diseases or interventions that display cyclic behaviour. Markov models are particularly suited to modelling chronic disease, where patients experience disease progression over time.5-7 These models use transition probabilities, which give the likelihood of moving to a particular state in the next cycle, given the present state in the current cycle. A Markov model can be written as a set of discrete difference equations of the form:

Embedded Image

where A(t) is the transition probability matrix.

The functional form of equation 1 is more comprehensive than the Markov system given in equation 2, since it is not restricted to transition probabilities or even first order terms. By considering a broader range of functions in our model, the switch from one state to another is not just time driven, but can be dependent upon other factors. As with Markov systems, these equations are based on the assumption of “no memory”, in that the transition from one model state to another depends entirely on the current state and is not influenced by events in previous time steps. For example, the likelihood that a smoker will make an attempt to quit smoking may depend on the number of previous quit attempts. While this is a limitation of the model, data pertaining to the impact of prior events is not widely available and a more complex model, such as a system of non-linear differential equations, would certainly decrease the performance of the model interface. In general, a pseudo-Markov model provides a simple and efficient way of modelling the costs and outcomes resulting from health care interventions, particularly for progressive, chronic diseases.5 6

The key activity in such modelling problems is in determining the most appropriate form of the function f ( Nt). This function must be carefully chosen in order to capture known or observed behaviour in the study population. Hence, it is good modelling practice to have a full understanding of the modelling problem before attempting to define the model equations. More details of the model assumptions are given in appendix 1 at the end of this article.


The interface was chosen after examining the needs of the end user and accessibility to the model interface, among other considerations. It was a requirement that the model interface be easy to use and should be made available over the internet. In addition, the model was to be available as a stand alone application, which did not require any special software to support the programme. Further requirements were that the model could be extended at any stage to include additional calculations or extra countries, that key variables could be altered by the user, and that the model should be robust in order to support multiple users and large data sets.

Therefore, the interface was developed using a Microsoft Visual Basic 6 front-end with a Microsoft Access 97 database back end. For the web version, the system was constructed around a Microsoft Visual Basic WebClass. This consists of an ASP page, which makes calls to various ActiveX DLLs. This handles user interactions within the interface, as well as calculation of the model equations and generating outputs in the form of tables and graphs. Further to this, the model equations were translated into a spreadsheet format (Microsoft Excel 97), which provided a testing environment and facilitated the sensitivity analysis.

The advantage of this approach is that a powerful yet flexible application can be produced in a relatively short development time. The stand alone model can be run on most standard computer systems without the need for any additional software support. The web version of the model is hosted by WHO8 and a standard web browser tool such as Microsoft Internet Explorer 4 will allow access to the model.


The model interface allows the user to amend some key parameters such as the cost, efficacy, and percentage using each of the different smoking cessation methods, the initial number in the model cohort, the discount rate, etc. For the purpose of this paper, the default results for the UK cohort of smokers are presented to demonstrate the possible outputs of the model. For details of the sources used for the default UK data, see appendix 2 on eTC( In order to determine the validity and comparability of our results with those obtained by other researchers, further calculations were made (not shown in model interface), which were directly compared with published studies.

Tables 1 and 2 show the number of cases of morbidity at any given year and the cumulative number of deaths associated with smoking related disease. It can be seen that smoking related diseases in the UK account for over five million cases of smoking related morbidity at 20 years and 2.4 million deaths over the 20 year period.

Table 1

Number of cases of morbidity associated with smoking related disease in the UK

Table 2

Cumulative number of cases of mortality associated with smoking related disease in the UK

The model predicts that 79 000 smokers will die from one of five smoking related diseases in the first year alone. Table 3 shows a breakdown of these deaths by disease and compares these results to those from Callum.9

Table 3

Comparative mortality and morbidity figures

After 20 years, it is estimated that 56% of the smoking population in the UK will be affected by or will have died from a smoking related illness (7.5 million out of 13.3 million). This is in agreement with UK/US studies, which show that about half of all smokers are eventually killed by smoking.10 The model also predicts that in 20 years 18% of the current smoking population will have died from a smoking related disease (2.4 million out of 13.3 million). As a comparison, using the figures from Callum9 given above, and assuming that the annual number of deaths stay the same over time, approximately 1.8 million smokers would die in the 20 years. The model prediction takes into account the increase in the risk of morbidity and mortality as the cohort ages.

Table 4 illustrates that after 20 years, the cumulative cost of smoking related morbidity is approximately £28.3 billion, when discounted at 6%, which is the discount rate recommended by the UK government.11 These costs are direct medical costs only and do not take into account lost productivity costs such as absenteeism from work or patient costs. The current model costs represent scaled 1999 prices. Using default data for the UK for a cohort of smokers, table 5 shows the total cost of treating smoking related disease in the first year of the model compared to the results from Parrott and colleagues.1

Table 4

Cumulative health care costs associated with smoking related disease in the UK

Table 5

Comparative health care costs

There are a variety of methods used when attempting to quit smoking (for example, pharmacological treatment, group counselling, “willpower”). Each method has a different cost and a different chance of success. In this model, the user can use a combination of methods to form a smoking cessation intervention strategy. Table 6shows the default smoking cessation strategy employed for the analysis of the UK smoking population. The default values for treatment efficacy were taken from the average of those given in a number of published studies.12-15 The default values for usage of the interventions were taken from Parrott and colleagues.1

Table 6

Smoking cessation intervention default strategy for UK

A smoking cessation strategy consisting of a combination of pharmacological treatment, general practitioner advice, etc, as shown in table 6, has a total cost of £103 575 877. From table 7, it can be seen that this smoking cessation strategy costs approximately £1200 per life year saved and £22 000 per death averted. An article published by Tengs and colleagues reports cost-effectiveness estimates for more than 500 life saving interventions, including smoking cessation therapies, which are shown to be more cost-effective than many other disease interventions.16 As a comparison with the HECOS model results, the cost per life year saved of smoking cessation advice as given in Tengs and colleagues ranges from $990 to $9800 (approximately £600–£6000).

Table 7

Potential impact of smoking cessation strategy in the UK


An extensive sensitivity analysis was performed to ensure that the model was robust and that small changes in key model parameters did not lead to a large variation in the results. A brief description of the analyses follows.

Firstly, the annual percentage of smokers who make an attempt to quit smoking was considered. The default for the UK, as obtained from Bridgwood,17 was increased in increments of 10% from 36% up to 96% and the result at 20 years was compared. The average effect of this increase was a reduction of 3675 in the number of cases of morbidity, a decrease in health care spending for smoking related disease of £35 million, and a reduction in smoking related mortality of 10 239 cases. The cost of smoking cessation intervention per death averted increases on average by £138 per increment over the same range, though the cost of smoking cessation intervention per life year saved is reduced on average by £123.

To examine the effect that uncertainty in the usage or efficacy of individual cessation treatments has on the overall results, the average efficacy rate was varied from 4.4% to 34.4%, in increments of 5%. An efficacy greater than 34.4% was assumed to be unachievable given the treatments currently available. A 5% change in the average efficacy of the smoking cessation strategy leads to an average change of 0.05% in cases of morbidity (approximately 2551 cases). Furthermore, this achieves an average 0.4% change in cases of mortality (8644 cases) and 0.1% change in the cost of health care (£42.3 million). By increasing the efficacy from 4.4% to 34.4%, the cessation intervention cost per death averted and cost per life year saved are decreased by 87% (£12 006 and £1058, respectively).

In the model, the percentage of long term quitters relapsing was given as a fixed rate per year.18 However, this may overstate the number of long term quitters who recommence smoking as, intuitively, the relapse rate should decrease the longer a person refrains from smoking. Hence, the relapse rate was reduced, in increments of 1%, from 6.9% to 0%. A decrease of 1% reduces the number of cases of morbidity over 20 years by an average of 2658, which decreases health care spending for smoking related disease by an average of £13.6 million and reduces smoking related mortality by an average of 5623. Furthermore, the cost of smoking cessation intervention per death averted and cost per life year saved decreases by an average of £974 and £64, respectively.

Forecasting costs in the future is subject to some degree of uncertainty, particularly as the economic climate and prospective improvements in health care may result in a decrease or increase in future costs. The health care costs in this model were discounted, though outcomes were not. The default discount rate for the UK was taken to be 6% as per UK government recommendations.11This value was varied from 0% through to 10%. A 1% change in the discount rate results in an average change of 8% in the total health care costs.


The HECOS model is a useful, friendly, flexible, and easily accessible interface. It is unique in that both the health benefits (for example, life years saved) and changes in smoking related health care costs can be simulated over time for the individuals in a population. Hence, the model estimates both health and economic consequences of smoking and smoking cessation.

By allowing users to change key inputs, the model is flexible enough to be useful to a variety of decision makers and can be used to simulate various smoking cessation methods or even new interventions. This flexibility also extends to the model programme which was designed as a database interacting with a visual interface, which can be easily adapted should any changes be required in the long term. For example, it is anticipated that the model will evolve so that it can be populated with new epidemiology or cost data or extended to include other countries as required. Internet technologies have opened up more opportunities for information dissemination and by making such models available over the web, a much wider audience can be reached.

The Office of Smoking and Health in the US Public Health Service has also developed software to permit rapid calculations of death, years of potential life lost, direct health care costs, indirect mortality costs, and disability costs associated with cigarette smoking.19 20 The software, entitled SAMMEC (smoking attributable mortality, morbidity, and economics costs), aims to provide the USA with data on the health consequences of smoking to policymakers and public health professionals. The SAMMEC software has been further developed and improved upon in recent years,21-23 and has been used to calculate US state estimates of Medicaid expenditures attributable to cigarette smoking. The US SAMMEC software has also been modified and used to estimate smoking attributable mortality in Mexico and Canada.24 25

By comparison, the HECOS model is an interactive model, which looks at the current smoking population in 25 countries and predicts the cost and consequences of smoking over a 20 year period for these populations. Furthermore, HECOS allows users to input and compare different smoking cessation strategies, at it is this feature which will be useful to health care planners and policy makers.

One common argument against smoking cessation is that it will increase health care spending in the long term, as it increases life expectancy and hence increases the lifetime cost of health care. A controversial study by Barendregt and colleagues concluded that if all smokers quit, there would be savings in health care costs, but only in the short term.26 However, such an argument can be applied to any life extending intervention. The costs should be offset against any health gain, such that the cost-effectiveness of an intervention should be considered. The authors themselves state that public health policy is concerned with health, and smoking therefore should be discouraged. In any case, it is true to say that for a relatively small initial outlay, smoking cessation interventions result in health gains, which in the long term reduce the cost of health care for smoking related diseases, releasing resources for other health care programmes.1 Some authors have questioned the conclusion of the article by Barendregt and colleagues, citing an underestimation of the differences in costs and health care use between smokers and non-smokers.27-31 Furthermore, studies in a number of countries, including the USA, UK, Canada, and China, do not support the notion that the tobacco industry provides some national economic benefit.32 It is felt that economic arguments in support of tobacco consumption do not take into account all of the associated costs or the reduction in the quality of life of smokers. This model evaluates the most visible costs associated with tobacco and these indicate that the economic burden of smoking is immense.


The authors are grateful for the contribution of the World Health Organization “European partnership project to reduce tobacco dependence”. This study was funded by Glaxo Wellcome Inc. Dr Susan Hogue is a full time employee in the Global Health Outcomes department at Glaxo Wellcome, Research Triangle Park, NC, USA.

model assumptions


At any time during their smoking career, people can change their smoking habits and may temporarily or permanently quit smoking. It is assumed that a smoker can be in one of three smoking states, namely a current smoker, a recent quitter or a long term quitter. Given that most attempts to quit do not last for more than a few days,33 we defined a long term quitter to be someone who has not smoked for more than one year. Figure 1 shows the relation between the three smoking states in this model.

Figure 1

Changes in smoking status.


Cigarette craving and withdrawal symptoms will have the most impact on those who have recently quit smoking, and it is this group that will benefit most from smoking cessation therapy. Therefore, in the model, it is assumed that smoking cessation aids are targeted at recent quitters and that withdrawal symptoms gradually subside over time. Subsequently, smoking cessation interventions increase the likelihood of a successful quit attempt and long term quitters should have a lower relapse rate compared to recent quitters. These observations are shown in fig 2.

Figure 2

Effect of cessation aid on smoking habit.

The impact of a one-off investment in smoking cessation was modelled by increasing the rate at which smokers successfully quit for the first year of the model.


Smokers are at risk from smoking related disease and may die prematurely as a result. Ex-smokers can also acquire smoking related diseases, but their risk of disease will be less than that of a current smoker. Figure 3 shows how health status can change for a smoker or an ex-smoker in the model. Note that the change from the no morbidity state to the diseased state is assumed to be irreversible.

Figure 3

Change of health status.

The smoking related morbidities included in this model were chronic obstructive pulmonary disease, asthma, chronic heart disease, stroke, lung cancer, and low birth weight pregnancies.


The model was constructed by considering the change in the health status and smoking behaviour in the smoking population over successive time steps of one year. In general, smoking habits are stable33 and a shorter time scale would not capture any change in smoking behaviour. Furthermore, disease and mortality rates are generally measured as a rate per year; therefore, a one year time interval was considered to be the most suitable for this model.

The smoking status of an individual in the model can be split into three discrete (non-overlapping) states, namely:

  • a current smoker;

  • a recent quitter (defined as an ex-smoker who has quit for less than one year);

  • a long term quitter (defined as an ex-smoker who has quit for more than one year).

Furthermore, the health status of an individual can also be split into three mutually exclusive states, namely:

  • no morbidity (healthy);

  • morbidity (not healthy but alive);

  • dead.

Altogether, an individual can be in one of seven model states according to the smoking and health status of that individual. Figure 4gives a schematic representation of how an individual can move from one state to another. Further schematic representations can be found oneTC ( From this, it can be seen that the number of individuals in a given stateSj, at time t+1,depends on the number in connected states at timet, that is:

Embedded Image

Figure 4

Transitions from the state “current smoker with no morbidity”. Quit = rate of quite attempts; Morb = Morb (a,t) = rate of morbidity; a = age/sex group; t = year.

The discrete difference equations used in the model were constructed using equation 3, with the transition from one state to another determined by the rate at which smoking behaviour changes (that is, quit rates, relapse rates), as well as disease and mortality rates. A full list of the model equations can be obtained from the author.

Death from non-smoking related causes are not captured in this model. This was because of an absence of comprehensive data pertaining to the relation between the development of smoking or non-smoking related disease.


For each year an individual is alive with a smoking related disease, they will accumulate health care costs. The model therefore estimates the cost of health care associated with smoking related disease over a 20 year period.

In general, people will prefer to have something today, rather than at a future time—they have a “time preference”. For example, we want the benefits today, but the costs to occur later. As this model predicts costs over 20 years, it is important to take into account the effect of time. In accordance with good economic practice, the future costs in this model werediscounted to the present time.34

From Drummond and colleagues35, ifP is the present value,Fn the future cost at yearn, and r is the discount rate, then future costs were discounted to the present value using the formula:

Embedded Image


Smoking behaviour and disease risks will vary according to age and sex. In general, more men smoke compared to women and smoking prevalence is higher in younger age groups. To capture this, the smoking population in the model is split into a number of subpopulations according to age and sex. The subpopulations considered in this model were based upon the work of Peto and colleagues36, with males aged 0–34, 35–69, and 70+, and females aged 0–34, 35–69, and 70+.

It is also noted that duration of smoking habit is a better predictor of morbidity than level of smoking.33 Therefore, as the smoking population ages, the risk of smoking related disease increases. Hence, in the model the morbidity and mortality rates were time dependent as well as dependent on age and sex.


In order to model the effect of smoking cessation, the interface runs two parallel calculations. In the first year of the model, one calculation moves a number of smokers from the recent quitters state to the long term quitters state, according to the efficacy of the smoking cessation strategy chosen. The parallel calculation assumes that the smoking cessation strategy did not take place. The results in subsequent years are then compared to ascertain the benefit of the incremental smoking cessation, which took place in the first year. This approach takes into account those who would have quit smoking anyway, and those who would have subsequently relapsed.

The number of life years saved from a smoking cessation intervention is calculated as follows:

  • those who die within model in year x, are said to have survived for x − 1 model years;

  • those who survive to the end of the model run are said to have survived 20 years;

  • the total number of years survived is: the number who survive x years multiplied by x years, summed over 20 years.

The number of life years saved through an intervention is the difference in the total years survived with an intervention, compared to the total life years survived without an intervention.


Contributed by Melanie Wakefield.

View Abstract
  • Figure 5: Transitions from the state recent quitter with no morbidity

    ALT="Figure 5: Transitions from the state recent quitter with no morbidity">



    Figure 6: Transitions from the state 'long-term quitter with no morbidity'

    ALT="Figure 6: Transitions from the state 'long-term quitter with no morbidity'">



    Figure 7: Transitions from the state 'current smoker with morbidity'

    ALT="Figure 7: Transitions from the state 'current smoker with morbidity'">




    Figure 8: Transitions from the state 'recent quitter with morbidity'

    ALT="Figure 8: Transitions from the state 'recent quitter with morbidity'">


    Figure 9: Transitions from the state 'long-term quitter with morbidity'

    ALT="Figure 9: Transitions from the state 'long-term quitter with morbidity'">


    Keys and Legends for Tables and Figures

    Key for Figure 5

    Relapse = rate of relapse after a quit attempt of less than one year; Morb = Morb (a, t)= rate of morbidity;

    a = age/gender group; t = year

    Key for Figure 6

    LTRelapse = rate of relapse after quitting for more than one year; Morb = Morb (a, t)= rate of morbidity;

    a = age/gender group; t = year; RR = relative risk of an ex-smoker compared to a current smoker

    Key for Figure 7

    Quit = rate of quit attempts; Death = Death (a, t)= rate of morbidity; a = age/gender group; t = year

    Key for Figure 8

    Relapse = rate of relapse after a quit attempt of less than one year; Death = Death (a, t)= rate of morbidity;

    a = age/gender group; t = year

    Key for Figure 9

    LTRelapse = rate of relapse after quitting for more than one year; Death = Death (a, t)= rate of morbidity;

    a = age/gender group; t = year; RR = relative risk of an ex-smoker compared to a current smoker





    Further details of data sources for the UK or any of the other countries included in the model can be obtained via the model interface or from the user-manual, which accompanies the model.

    Data Source



    Action on Smoking and Health, 1998 []

    Uptake of smoking

    ASH web based statistics on the incidence of smoking in the UK. Data is for the year 1996.

    Action on Smoking and Health, 1999b []

    Incremental absenteeism in smokers

    ASH web based statistics on the average duration of absenteeism for smokers compared to non-smokers.

    Akehurst, 1994 []

    Smoking cessation efficacy

    This study considers the cost-effectiveness of the use of nicotine (Nicorette) nasal spray (NNS) to assist patients to quit smoking, with the main effectiveness measure used being life years gained. The scale of gain is estimated by taking the effect on NNS on quit rates and estimating the effect of the changes in quit rates in future mortality from various diseases.

    Bridgwood, 1998 []

    Quit rate

    As part of this follow-up survey, the quit rate during 1997 for the UK was estimated. Additionally, data from 1996 and 1997 on smoking and smoking cessation behaviour are compared.

    British Heart Foundation, 1998 []

    CHD and stroke prevalence, incidence, mortality, absenteeism

    The 7th edition of the Coronary Heart Disease Statistics provides the most recent statistics related to the prevalence, incidence, mortality, causes and effects of CHD and related diseases of the circulatory system.

    British National Formulary, 1998 []

    Smoking cessation intervention costs

    The BNF is a joint publication of the British Medical Association and the Royal Pharmaceutical Society of Great Britain. The BNF presents information on the prescribing, dispensing and administration of medicines, and basic net prices as an indication of relative cost. The cost data were based on 1998 prices.

    Callum, 1998 []

    Percentage morbidity and mortality attributable to smoking; COPD, CHD, lung cancer mortality

    Booklet containing statistics pertaining to the number of deaths estimated to be caused by smoking by disease. The data are national data for the UK for 1995.

    Campbell, 1997 []

    Asthma mortality

    This study considered trends in asthma mortality by age group in England and Wales. The data were collected between 1983-95.

    Cancer Research Campaign, 1998 []

    Lung cancer incidence and prevalence

    This factsheet consists of national statistical data for the year 1995.

    Central Intelligence Agency, 1998 []

    Socio-demographic data; GDP per capita

    The World Factbook is prepared by the Central Intelligence Agency for the use of US Government officials and agencies. Sociodemographic data from 1998.

    Clark, 1998 []

    Smoking attributable COPD morbidity

    This study examined the risk of cigarette smoking in the development of chronic obstructive pulmonary disease (COPD) in 100 people (80 current smokers and 20 non-smokers) between the ages of 35-65 years.

    Cohen, 1993 []

    Risk reduction for ex-smokers: CHD and cancer

    This study reports a review of cost-benefit analyses (CBAs) and cost-effectiveness analyses (CEAs) in the economics of smoking cessation. Data were collected between 1951-1991.

    Doll, 1994 []

    Mortality by disease: smokers, ex-smokers and never smokers

    The study considered a cohort of 34,439 British male doctors who replied to a postal questionnaire in 1951. 10,000 died during the first 20 years and another 10,000 died during the second 20 years. The excess mortality was mainly from diseases which can be attributable to smoking. The data were collected between 1951-1991.

    European Community Respiratory Health Survey, 1996 []

    Asthma prevalence

    The prevalence of asthma in 1994 is reported in this study. The article discusses the variation in the self reported attacks of asthma and asthma symptoms across Europe.

    Gellert, 1990 []

    Asthma prevalence

    The study considered a cohort of patients and management of asthma symptoms from case records (1,032 out of 11,148 records (9.3%)) in a London inner city general practice. The data were collected between 1986 and 1989.

    General Household Survey, 1996 []

    Smoking prevalence

    In this bulletin, containing statistical data about smoking in England from 1976 to 1996, the prevalence of cigarette smoking in 1994 among adults aged 16 and over are presented, by both age and gender.

    Green Book, 1997 []

    Discount rate

    Government publication recommending the discount rate to be used for costing studies in the UK.

    Jarvis, 1997 []

    Recidivism rates

    This paper considers the natural history of smoking cessation in the general population. It considers the relation of cessation to age, gender and social influences. The main focus is on the outcomes of all attempts at cessation, many of which are unaided. It summarises data from a variety of sources, the majority of which are for the UK, e.g. the General Household Survey (GHS) and the British National Child Development Study (NCDS).

    Jorenby, 1999 []

    Data on smoking cessation intervention

    The study reports the resuts of double-blind, placebo-controlled comparison of smoking cessation therapies. Sustained-release bupropion (244 subjects), a nicotine patch (244 subjects), bupropion and a nicotine patch (245 subjects), and placebo (160 subjects) were considered.

    Law, 1995 []

    Smoking cessation intervention efficacy

    The study analyzed efficacy of intervention data from 188 randomized controlled trials.

    Lung and Asthma Information Agency, 1996 []

    COPD mortality

    This data is national statistical data for the years 1990-92.

    Meredith, 1996 []

    Asthma incidence

    The study considered data from a national survey for the years 1982-92.

    Mugford, 1995 []

    Cost of LBW

    This article considers the cost per case for neonatal care after a review of international low birth weight cost data. The 1994 cost data were given in GBP. In the model, costs were inflated to 1998/99 prices.

    Parrott, 1998 []

    Cost of COPD, CHD, stroke and lung cancer; Smoking cessation intervention efficacy and usage

    This article examines the case for smoking cessation. It includes an estimate of the costs of smoking related diseases to the healthcare service in England. The cost data were based on 1991 prices. In the model, costs were inflated to 1998/99 prices.

    PSSRU, 1997 []

    Smoking cessation intervention costs

    This booklet contains cost data based on work at the University of Kent. The cost data were from 1996/97. In the model, these were inflated to 1998/99 prices.

    Raw, 1999 []

    Smoking cessation intervention efficacy

    Meta-analysis of a three-arm study of efficacy of smoking cessation interventions: nicotine patch, GP consulation and group therapy. Data were collected between 1996-1997.

    Roberts, 1998 []

    Risk reduction for ex-smokers: CHD

    The study considered 760 patients from a practice list of 2,040, who were recruited from and followed up in health promotion clinics, routine practice nurse appointments, or routine doctors' surgeries. The data were collected in 1996.

    SAMMEC, 1990 []

    Relative risks

    Analysis performed using the Smoking-Attributable Mortality, Morbidity, and Economic Cost (SAMMEC) software. Data from 1990.

    Sullivan, 1993 []

    Cost of asthma

    This article considers a British cost-of-illness study, which estimated the cost of asthma in a hospital based care setting compared to the cost for asthma patients treated with ambulatory care. The cost data was from 1988. In the model, costs were inflated to 1998/99 prices.

    The UK Office for National Statistics, 1998 []

    Population statistics

    National statistical data for 1995.

    US Dept of Health and Human Services, 1990 []

    Recidivism rate

    Examination of epidemiologic, clinical, and experimental data on active smoking and evaluation of associations of smoking with disease in the US, compiled by the Federal Department of Health and Human Services. Data collected since 1964.

    WHO Statistical Information Service, 1996 []

    LBW prevalence

    A guide to all statistical information at WHO, by topic or disease. The WHOSIS (WHO Statistical Information System) contains country data and epidemiological information available from the World Health Organization. Data from 1999.

    World Health Organization, 1998 []

    Tobacco consumption and total annual deaths from smoking

    Web based database produced by the WHO of country profiles detailing smoking-related mortality and morbidity, smoking prevalence and tobacco consumption, production, and control measures. Data for 1990.


  • website extra: Supplemental data and schematic representations appear on the Tobacco Control website

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.